

3 September 2025

Dear Shareholder

ANNUAL GENERAL MEETING (2025 AGM)

Notice is hereby given that the 2025 AGM of Arovella Therapeutics Limited (Arovella or the Company) will be held as a virtual meeting (Meeting or 2025 AGM) at 11.00am (AEDT) on Thursday, 30 October 2025. The Meeting will be held via an online platform.

Arovella advises that in accordance with sections 110C-110K of the Corporations Act 2001 (Cth), no hard copy of the Notice of Annual General Meeting and Explanatory Notes (Notice) will be circulated other than to shareholders who have expressly requested a hard copy. These documents can be accessed on the Company's website at <https://www.arovella.com/asx-announcements> and via the ASX Market Announcements Platform under the Company's ASX Code (ALA).

If you have nominated an email address and elected to receive electronic communications from the Company, you will receive an email with a link to an electronic copy of the Notice of Meeting.

Director Nominations

Under Listing Rule 3.13.1, the Company advises that the closing date for director nominations is 11 September 2025.

Your Vote is Important

The business of the 2025 AGM is important to all Shareholders and therefore it is important that Shareholders vote. Lodging a completed proxy is the simplest way to vote at the AGM.

The Company encourages shareholders to submit their votes in advance of the 2025 AGM as this will provide the Company with the best opportunity to prepare for the meeting. However, votes may also be submitted during the 2025 AGM. Proxy forms can be lodged online, by post or in person by following the proxy lodgement instructions on the proxy form. Proxy forms must be received by the Company's share registry, Automic, by 11am (AEDT) on Tuesday, 28 October 2025. Proxy forms received later than this time will be invalid.

If it becomes necessary or appropriate to make alternative arrangements for the holding or conducting of the 2025 AGM, the Company will make further information available through the ASX Market Announcements Platform and on its website.

Shareholder Communication Elections

Recent changes to the Corporations Act provide for shareholders electing and requesting to receive documents (including notices of meeting and the annual financial report) electronically or in hard copy. You can make a standing election and/or request to receive some or all of your communications from the Company in physical or electronic form.

Shareholders can also elect not to receive certain documents, including the annual financial report.

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



We encourage you to provide your email address so we can communicate with you electronically and you are provided with information regarding the Company more efficiently and sustainably.

If you have made a prior election or request to receive documents in a certain manner then that election will continue to apply until such time as you notify the Company that you change your election or request. Any shareholder who has not made a prior election and/or request to receive documents in a certain form will be treated by the Company as having elected to receive all documents in electronic form.

If you wish to update your communication preference, please refer to the insert titled "Update your details" or contact our share register, Automic below:

Shareholder queries in relation to the Meeting

Shareholders can contact the Company's Registry with any questions prior to the meeting via email listed below.

Telephone (within Australia): 1300 288 664

Telephone (outside Australia): +61 2 9698 5414

Email: hello@automicgroup.com.au

Website: <https://investor.automic.com.au/>

Yours faithfully

Tim Luscombe

Company Secretary

Arovella Therapeutics Ltd

investor@arovella.com